George Demetri - 21 Jun 2022 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role
Director
Signature
/s/ Ariel Hurley, Attorney-in-Fact
Issuer symbol
BPMC
Transactions as of
21 Jun 2022
Net transactions value
+$241
Form type
4
Filing time
30 Jun 2022, 21:53:27 UTC
Previous filing
14 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Purchase $827 +10 +0.17% $82.66 5,822 13 Jul 2021 Direct
transaction BPMC Common Stock Sale $586 -10 -0.17% $58.56 5,812 17 Mar 2022 Direct
transaction BPMC Common Stock Award $0 +2,600 +45% $0.000000 8,412 21 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Award $0 +5,300 $0.000000 5,300 21 Jun 2022 Common Stock 5,300 $50.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders.